Orange Book product · Generic (ANDA)
OLMESARTAN MEDOXOMIL
OLMESARTAN MEDOXOMIL
At a glance
Feb 22, 2019
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Feb 22, 2019
7 yr 5 mo ago
Today
Pharmaceutical detail
Active ingredient
OLMESARTAN MEDOXOMIL
Strength
5MG
Dosage form
TABLET
Route
ORAL
TE code
AB
Application
ANDA 211049
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of OLMESARTAN MEDOXOMIL
- 2002BENICARBrand (NDA)
NDA 021286 · COSETTE
- 2024OLMESARTAN MEDOXOMILGeneric (ANDA)
ANDA 210682 · CADILA PHARMS LTD
- 2024OLMESARTAN MEDOXOMILGeneric (ANDA)
ANDA 205499 · HETERO LABS LTD V
- 2024OLMESARTAN MEDOXOMILGeneric (ANDA)
ANDA 206227 · CHARTWELL RX
- 2023OLMESARTAN MEDOXOMILGeneric (ANDA)
ANDA 207480 · AMNEAL
- 2023OLMESARTAN MEDOXOMILGeneric (ANDA)
ANDA 217399 · MSN
- 2022OLMESARTAN MEDOXOMILGeneric (ANDA)
ANDA 206720 · PRINSTON INC
- 2020OLMESARTAN MEDOXOMILGeneric (ANDA)
ANDA 208659 · INVENTIA
- 2020OLMESARTAN MEDOXOMILGeneric (ANDA)
ANDA 090237 · SANDOZ
- 2019OLMESARTAN MEDOXOMILGeneric (ANDA)
ANDA 206372 · MICRO LABS
- 2019OLMESARTAN MEDOXOMILGeneric (ANDA)
ANDA 207135 · UMEDICA
- 2019OLMESARTAN MEDOXOMILGeneric (ANDA)
ANDA 210552 · QILU
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
